The management of patients with advanced carcinoid tumors and islet cell carcinomas.
about
Surgical treatment of malignant carcinoid tumours of the appendixClinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCCThe treatment of primary and metastatic hepatic neoplasms using percutaneous cryotherapy.Acute thrombocytopenia: An uncommon complication occurring following transarterial chemoembolization in a patient with neuroendocrine hepatic metastasesReview article: current status of gastrointestinal carcinoids.Progress in the treatment of neuroendocrine tumors.Transplantation for liver and biliary cancer.New treatment options for patients with advanced neuroendocrine tumors.Systematic review: the use of somatostatin or octreotide in refractory diarrhoea.Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.Embolisation of cancer: what is the evidence?The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours.Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors.Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoeaRegional therapy of liver metastases.Interventional treatment of the carcinoid syndrome.Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors.Hepatic neuroendocrine metastases: chemo- or bland embolization?Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques.The role of cytoreductive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas.Comparison of survival between malignant neuroendocrine tumours of midgut and pancreatic origin.Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC).The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursMalignant neoplasms of the appendix.Emerging therapies for the treatment of patients with advanced neuroendocrine tumors.Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases.Medical management of pancreatic neuroendocrine tumors.Liver embolizations in oncology: a review. Part I. Arterial (chemo)embolizations.Biology and treatment of metastatic gastrointestinal neuroendocrine tumors.Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors.A woman with metastatic pancreatic neuroendocrine tumor.Minute liver metastases from a rectal carcinoid: A case report and review.Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumoursIntra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.Multimodal liver-directed management of neuroendocrine hepatic metastasesOrthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors.Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment.
P2860
Q28257964-549522BD-0EBC-4C6D-86B7-D84779C173C9Q28289376-76A63D18-57B6-46A1-9A93-D0ED85C44FD5Q30477022-B86D262A-6226-49EB-A18F-20094130A682Q33424372-AF7D82B5-012B-4BFB-9C87-AB223068A694Q33548211-42D6D9C6-0649-4236-9D73-35299C2B48A6Q33643643-09A9D510-E1AE-43A8-81A9-583B7BEF2895Q34110988-2128CF3F-B7CB-42A5-B0A1-45B8B63A168FQ34173336-EB046E45-53C2-4363-BD88-5ED802B9796EQ34458946-1839DDF8-5375-4590-89C0-74E51CE2B7B0Q34498450-57D1A6AF-7CE8-45A4-AA61-BDA62E93B11FQ34533357-75CF7816-560F-4DCF-84FA-ECCEC5F8A6AFQ34564262-D9E72802-714F-4381-B4DA-1D9C1B812352Q34573056-46F8F472-C96C-442A-A5F8-78A87398ED0DQ34769975-F9933F28-375B-4CED-854E-1543A3C1810AQ35350975-B0F3BC04-B940-4B37-95D8-892664D20E47Q35876422-426ACAE5-E982-4BBC-BA85-2F0B0F59513BQ35915017-108CFA31-EC4F-4AB4-9224-EDD2D8D73529Q35915022-6B257476-4094-49C9-88B8-A28059E96AA5Q35930191-EB107D8F-1FCA-4267-8F09-9C1E3598B841Q36205891-C5FFA093-4FA8-462F-853C-03882827A2C4Q36409960-8DFBF7C5-EAFF-4055-9558-BEA7841DF097Q36617981-F8F9D599-778E-4441-BAC3-84A8809165E9Q36621918-C34B44D3-1D29-4CF8-8C30-D847BB5E3130Q36755905-B4079FA6-D48F-4ED5-8BB9-19B7E1E02E89Q36796933-E7CB8B07-FCFB-4FEF-9F36-2EA8DA0BA3D7Q36866607-FF9B6F40-FB3C-4B12-9FB1-52E963AAAF16Q36980633-BDDD00D6-6B5C-4E61-8510-627EEF6B0D9AQ37009032-D0E2221E-4EF3-4DC8-AA95-CD96B509F5EAQ37054978-4BCBF090-AD3D-4E6F-B540-5BA3587FDEBBQ37077832-38489FB7-8E91-4038-AAB8-1C1930962F41Q37277977-CE0CCE4E-A214-4BCF-804E-CBD0F06F5E5DQ37384675-42AC8B6A-72B8-49F1-B562-33272959F8C1Q37584857-8C58CFA2-78D6-41DA-B71E-D2F84DF6D609Q37821276-F3EA4C38-B015-4E7D-B5ED-164B893BE31CQ37995522-B7AA0E55-F20B-4BCD-AC72-A29EED3567A6Q38285656-C0CBD6DB-6452-4A41-A8D8-C6A6C8E1DBA4Q38693622-038E52CB-ADB8-46C9-8D21-D27B0493B76FQ38897797-A18E5A79-B819-4265-8F9C-21B7A5509ABAQ39339221-486F9E04-7133-4D76-A6FA-087F0B47EC72Q39491049-61ACB828-0535-4663-87B9-5DFD1AC3D466
P2860
The management of patients with advanced carcinoid tumors and islet cell carcinomas.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
The management of patients with advanced carcinoid tumors and islet cell carcinomas.
@en
The management of patients with advanced carcinoid tumors and islet cell carcinomas.
@nl
type
label
The management of patients with advanced carcinoid tumors and islet cell carcinomas.
@en
The management of patients with advanced carcinoid tumors and islet cell carcinomas.
@nl
prefLabel
The management of patients with advanced carcinoid tumors and islet cell carcinomas.
@en
The management of patients with advanced carcinoid tumors and islet cell carcinomas.
@nl
P2093
P1476
The management of patients with advanced carcinoid tumors and islet cell carcinomas.
@en
P2093
Johnson CM
Kunselman S
Martin JK Jr
McKusick MA
Moertel CG
Nagorney DM
P304
P356
10.7326/0003-4819-120-4-199402150-00008
P407
P577
1994-02-01T00:00:00Z